179 related articles for article (PubMed ID: 16151809)
1. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.
Johnston D; Reynolds SR; Bystryn JC
Cancer Immunol Immunother; 2006 Apr; 55(4):412-9. PubMed ID: 16151809
[TBL] [Abstract][Full Text] [Related]
2. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
Johnston D; Zaidi B; Bystryn JC
Cancer Immunol Immunother; 2007 Aug; 56(8):1133-41. PubMed ID: 17139492
[TBL] [Abstract][Full Text] [Related]
3. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K
J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512
[TBL] [Abstract][Full Text] [Related]
4. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Johnston D; Bystryn JC
Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
[TBL] [Abstract][Full Text] [Related]
6. A novel vaccine delivery system using immunopotentiating fusogenic liposomes.
Hayashi A; Nakanishi T; Kunisawa J; Kondoh M; Imazu S; Tsutsumi Y; Tanaka K; Fujiwara H; Hamaoka T; Mayumi T
Biochem Biophys Res Commun; 1999 Aug; 261(3):824-8. PubMed ID: 10441509
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.
Zhou F; Rouse BT; Huang L
Cancer Res; 1992 Nov; 52(22):6287-91. PubMed ID: 1384958
[TBL] [Abstract][Full Text] [Related]
8. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant.
Li J; Guo J; Su Z; Hu M; Liu W; Wei Q
Int Immunol; 2011 May; 23(5):327-34. PubMed ID: 21447603
[TBL] [Abstract][Full Text] [Related]
10. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
[TBL] [Abstract][Full Text] [Related]
11. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
[TBL] [Abstract][Full Text] [Related]
13. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
[TBL] [Abstract][Full Text] [Related]
15. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
[TBL] [Abstract][Full Text] [Related]
16. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
18. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine.
Okamoto T; Kaneda Y; Yuzuki D; Huang SK; Chi DD; Hoon DS
Gene Ther; 1997 Sep; 4(9):969-76. PubMed ID: 9349434
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity.
Kawamura K; Kadowaki N; Suzuki R; Udagawa S; Kasaoka S; Utoguchi N; Kitawaki T; Sugimoto N; Okada N; Maruyama K; Uchiyama T
J Immunother; 2006; 29(2):165-74. PubMed ID: 16531817
[TBL] [Abstract][Full Text] [Related]
20. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route.
Ge W; Li Y; Li ZS; Zhang SH; Sun YJ; Hu PZ; Wang XM; Huang Y; Si SY; Zhang XM; Sui YF
Cancer Immunol Immunother; 2009 Feb; 58(2):201-8. PubMed ID: 18523770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
